What evidence prompted sapropterin's therapeutic consideration?

The idea to use sapropterin (a synthetic BH4 cofactor) in PKU came from several lines of evidence:

- Biochemical rationale: PAH, the enzyme blocked in PKU, requires BH4 as a cofactor. Providing BH4 could boost residual PAH activity in some patients.

- BH4-responsive PKU observations: Clinically, a subset of PKU patients showed marked reductions in blood phenylalanine (Phe) and increased Phe tolerance after BH4/sapropterin administration, suggesting their enzyme function could be enhanced by cofactor supplementation.

- Early clinical studies: Case reports and small trials demonstrated meaningful Phe reductions and dietary liberalization in responders, supporting the feasibility of cofactor therapy.

- Genotype-phenotype data: Responders tended to have milder PAH mutations with some residual enzyme activity, helping identify who might benefit.

- Responsiveness testing: The concept of a BH4-response test (a short trial of sapropterin with measurement of Phe changes) emerged as a way to select patients for long-term therapy.

- Regulatory validation: Randomized/controlled trials and safety data led to FDA approval (2007) for sapropterin in BH4-responsive PKU, with use tied to demonstrating a clinical Phe reduction after a test dose.

In short, sapropterin’s therapeutic consideration was prompted by evidence that some PKU patients have residual PAH activity that can be enhanced by BH4, leading to lower Phe levels and greater dietary flexibility in responders.